DHL Supply Chain expands pharma logistics operations in France

DHL Supply Chain has expanded its specialised logistics services for the life sciences and healthcare sector in France through a long-term partnership with Sanofi, a global healthcare company.

DHL Supply Chain will provide warehousing, inventory management, picking and packing, and order fulfilment across three key sites in France - Amilly Distribution, Croissy-Beaubourg, and Saint-Loubès, according to an official release from DHL.

Hendrik Venter, Regional CEO, DHL Supply Chain EMEA says: "This partnership strategically expands our existing, multi-country collaboration with Sanofi. By leveraging our combined global reach and scale and expertise in Healthcare in EMEA, we unlock significant synergies to optimise customer supply chains and create greater resilience. By actively scaling our Life Sciences & Healthcare division, we will solidify our position as the leading provider of end-to-end solutions across the entire value chain. This not only increases value for our customers by supporting them in meeting changing patient needs, but ultimately improves patient outcomes."

Ruth Beadle, Head of Global Supply Chain, Sanofi adds: "We are delighted to partner with DHL to continue delivering the highest quality products in a sustainable way from France. We strongly believe that the Amilly, Croissy Beaubourg and Saint-Loubès distribution centres with its employees will continue to exercise the same strive for excellence with DHL through a new journey that will bring the most value to our customers and patients in France and all around the world".

The partnership is further reinforced by DHL's experience across various segments including pharmaceuticals, biopharmaceuticals, consumer health, vaccines, medical devices, clinical trials, hospitals, and healthcare establishments, says the release.

Nico Schütz, CEO, DHL Supply Chain France adds: "Our dedicated team is highly trained and experienced in handling the specific requirements of life science products. We have the infrastructure, technology and know-how to ensure quality assurance and rigorous compliance with French regulation. This strategic agreement serves as a lever to further develop our life sciences and healthcare division in France and the wider EMEA region."